ADRO Aduro Biotech, Inc.

11.40
+0  (0%)
Previous Close 11.40
Open 11.45
Price To book 3.41
Market Cap 775.18M
Shares 67,998,000
Volume 251,846
Short Ratio 29.15
Av. Daily Volume 283,715

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 1H 2017.
CRS-207
Gastric cancer
Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas - ECLIPSE trial
Pancreatic cancer
Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial
Pancreatic cancer
Phase 1/2 dosing initiated March 2016.Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
Epacadostat and CRS-207 - SEASCAPE
Ovarian cancer
Phase 2 trial to be initiated 1H 2017 with early data due 2H 2017.
CRS-207
Mesothelioma - cancer

Latest News

  1. Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017
  2. Aduro BioTech, Inc. :ADRO-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
  3. Aduro Biotech to Host Research and Development Day in New York
  4. Aduro Biotech Awarded East Bay Innovation Award for its Contributions in Life Sciences and the San Francisco East Bay Community
  5. ADURO BIOTECH, INC. Financials
  6. Aduro Biotech Announces Upcoming Data Presentations at the 2017 American Association for Cancer Research Annual Meeting
  7. Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4
  8. Aduro Biotech Announces Upcoming Data Presentations at the Keystone Symposia on Cancer Immunology and Immunotherapy Conference
  9. Aduro Biotech reports 4Q loss
  10. Aduro Biotech reports 4Q loss
  11. ADURO BIOTECH, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
  12. ADURO BIOTECH, INC. Files SEC form 10-K, Annual Report
  13. Aduro Biotech Announces Fourth Quarter and Full Year 2016 Financial Results
  14. Aduro Biotech to Present at Two Investor Conferences in March
  15. Aduro Biotech to Present at the Leerink Partners 6th Annual Global Healthcare Conference
  16. Aduro BioTech, Inc. breached its 50 day moving average in a Bullish Manner : ADRO-US : February 1, 2017
  17. Aduro Biotech Announces Appointment of Leading Immunotherapy and Oncology Experts to Scientific Advisory Board
  18. Aduro (ADRO) Inks License Agreement with Stanford University
  19. Aduro Biotech Enters into Exclusive License Agreement for Proprietary Neoantigen Identification Technology
  20. ETFs with exposure to Aduro BioTech, Inc. : January 17, 2017